Biocon founder and chairperson Kiran Mazumdar Shaw says the cost of one vial is around 8000 rupees and people would need 4 vials.
Drugs Controller General of India gave approval to Biocon’s COVID-19 drug, Itolizumab to deal with moderate to severe acute respiratory disease caused by COVID-19. This the first novel therapy in the world to be approved for COVID-19. A single drug of Itolizumab is for 8000 rupees and a single patient needs at least a therapy of this course. A single therapy consists of 4 vials and therapy costing 32000 rupees.
The founder even told the media that the drug will be available in the market in a matter of 120 days. She even added that even if a vaccine is available by the end of the year, there is no assurance that there will be no reinfection. Thus, the state should be in preparedness.